Neuralink Raises Additional $43 Million

Neuralink Raises Additional $43 Million

Neuralink, the brain-computer interface company co-founded by Elon Musk, has raised an additional $43 million in venture capital, as indicated by a recent SEC filing. This funding boost expands the company's previous investment tranche from $280 million to a total of $323 million.

Transaction Snapshot

  • Deal Value: $43 million, total now at $323 million
  • Valuation: $5 billion (based on June report)
  • Deal Date: Early August
  • Investors: Included Peter Thiel’s Founders Fund among thirty-two investors
  • Founders: Elon Musk (Co-founder)

Neuralink, established in 2016, is pioneering in the development of implantable chips designed to read brain waves. The company's technology involves a sewing machine-like device that implants ultra-thin threads into the brain, connected to a custom chip with electrodes capable of neuron group information capture. These innovations are aimed at enhancing the existing brain-signal-reading implant technology by introducing wireless capabilities and increasing electrode count.

Despite not disclosing its valuation recently, a June report by Reuters placed Neuralink's valuation at around $5 billion, following privately-executed stock trades. This latest funding round follows FDA approval in May for human clinical trials under an investigational device exemption, a significant step forward for the company.

However, Neuralink faces increasing scrutiny and controversy. Allegations include a toxic workplace culture, with reports from former employees describing a "culture of blame and fear." This has led to significant turnover among founding scientists and management issues, reportedly exacerbated by Elon Musk's direct communication approach with junior staff.

Concerns extend to the company's research practices, particularly involving animal testing. In 2022, the Physicians Committee for Responsible Medicine (PCRM) accused Neuralink and its former research partner, UC Davis, of mistreating monkeys used in hardware testing. Issues cited include psychological distress, chronic infections, and complications during surgeries, allegedly rushed to meet Musk's demand for quick results. While a federal investigation by the USDA found no evidence of animal welfare violations, except a self-reported incident from 2019, the PCRM has contested these findings.

As of November 2023, Neuralink faces further challenges with U.S. lawmakers urging the SEC to investigate the company for allegedly omitting details about animal deaths in its implant surgeries. This adds another layer of complexity to Neuralink's journey as it navigates technological breakthroughs amidst growing ethical and regulatory concerns.

📌 If you want more of this, subscribe to our newsletter - bite-sized tips and data to help you plan and execute your exit or capital raise.

Back to blog